Literature DB >> 19906258

CSF biomarkers: pinpointing Alzheimer pathogenesis.

Niklas Mattsson1, Kaj Blennow, Henrik Zetterberg.   

Abstract

Intense research during the last decades has resulted in an unprecedented accumulation of knowledge regarding the pathogenesis of Alzheimer's disease. Primarily, the focus has been directed toward amyloid and tau pathology and their relations to synaptic and neuronal loss. However, as the complexity of the disease becomes increasingly evident, the importance of other factors, such as inflammation, oxidative stress, and mitochondrial dysfunction, grow apparent. Here, we review available CSF biomarkers for these pathological processes. We also consider their usability in clinical practice and in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906258     DOI: 10.1111/j.1749-6632.2009.04944.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  26 in total

1.  PUTATIVE CSF PROTEIN BIOMARKER CANDIDATES FOR AMNESTIC MILD COGNITIVE IMPAIRMENT.

Authors:  Scott E Counts; Elliott J Mufson
Journal:  Transl Neurosci       Date:  2010-03-01       Impact factor: 1.757

2.  Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis.

Authors:  Christina Sundal; Matt Baker; Rosa Rademakers; Oluf Andersen; Virginija Karrenbauer; Marte Gustavsen; Sahl Bedri; Anna Glaser; Kjell-Morten Myhr; Kristoffer Haugarvoll; Henrik Zetterberg; Hanne Harbo; Ingrid Kockum; Jan Hillert; Zbigniew Wszolek
Journal:  Eur J Neurol       Date:  2014-10-13       Impact factor: 6.089

Review 3.  Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.

Authors:  Eric M Reiman; Jessica B S Langbaum; Pierre N Tariot
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 4.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

5.  Use of biomarkers in clinical trials of Alzheimer disease: from concept to application.

Authors:  Liyong Wu; Pedro Rosa-Neto; Serge Gauthier
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

6.  [The future of biomarkers in dementia diagnostics].

Authors:  R Zimmermann; J Kornhuber; P Lewczuk
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

Review 7.  The future of blood-based biomarkers for Alzheimer's disease.

Authors:  Kim Henriksen; Sid E O'Bryant; Harald Hampel; John Q Trojanowski; Thomas J Montine; Andreas Jeromin; Kaj Blennow; Anders Lönneborg; Tony Wyss-Coray; Holly Soares; Chantal Bazenet; Magnus Sjögren; William Hu; Simon Lovestone; Morten A Karsdal; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2013-07-11       Impact factor: 21.566

8.  Cerebrospinal fluid β-amyloid 1-42 correlates with rate of progression in Alzheimer's disease.

Authors:  George S Vlachos; George P Paraskevas; Dimitris Naoumis; Elizabeth Kapaki
Journal:  J Neural Transm (Vienna)       Date:  2012-03-30       Impact factor: 3.575

9.  Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.

Authors:  Niklas Mattsson; Henrik Zetterberg; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-08

10.  Cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and cognition in aging and Alzheimer disease.

Authors:  Jasmine Ramcharitar; Steffen Albrecht; Veronica M Afonso; Vikas Kaushal; David A Bennett; Andrea C Leblanc
Journal:  J Neuropathol Exp Neurol       Date:  2013-09       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.